Special Issue "Lung Cancer & COVID 19: Lessons, Experiences, Startegies"
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Infectious Agents and Cancer".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 3930
Special Issue Editors
Interests: cancer; metastases; mesothelioma; targeted therapies; genetics
Special Issues, Collections and Topics in MDPI journals
Dr. Torsten Gerriet Blum
Interests: thoracic oncology; lung cancer; interstitial lung diseases; diagnostics; biomarkers; screening; systemic therapies
2. Pneumology Vanvitelly-COVID Unit A.O. dei Colli Hospital Monaldi, 80131 Naples, Italy
Interests: metabolic perturbation of respuiratory diseases; lung cancer immune evasion (mechanisms and therapy); tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer patients are highly vulnerable to SARS-CoV-2 infections due to several causes, including their immunocompromised state due to antineoplastic therapies, use of steroids, comorbidities and frequently advanced age, and frequent hospital visits. The clinical pictures of the infection can vary from mild flu-like conditions to severe pneumonia, which can evolve to acute respiratory alveolar damage (ARDS) and multiorgan failure. Moreover, the cytokine storm is implicated in the generation of aberrant immunological responses against the virus, which ultimately produce lung parenchymal acute and severe damage responsible for evolution to chronic fibrosis and, in worse cases, patient death. This evidence has led to clinical approval of tocilizumab for the treatment of COVID-19-associated severe pneumonia rapidly evolving toward acute respiratory distress syndrome (ARDS). The persistence of the COVID-19 pandemic forces clinicians and researchers to reflect on the already available data to generate novel models for cancer patient management, from diagnosis to treatment, as well as for adverse events and complications. The goal of the present issue is to summarize, according to a multidisciplinary perspective, the lessons and experiences derived from the pandemic waves and to design strategies for future co-existence with SARS-CoV-2 to ensure safer and better outcomes for cancer patients.
Dr. Giulia M Stella
Dr. Torsten Gerriet Blum
Prof. Dr. Andrea Bianco
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
